Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese
× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

CML and dasatinib

  • Emma-Jane McDonald
  • Emma-Jane McDonald's Avatar Topic Author
9 years 8 months ago #958 by Emma-Jane McDonald
CML and dasatinib was created by Emma-Jane McDonald
I was hoping for some advice about a patient of mine with CML. He was diagnosed about 10 months ago in chronic phase and was commenced on imatinib. He didn’t tolerate this very well, mainly having symptoms of nausea so we switched him to dasatinib. He is feeling better than he did when he was on imatinib but is still not feeling great. He has very non-specific symptoms of lethargy, hip aches, nausea and indigestion, his mood is also a bit low which I am sure is not helping but I was wondering what your experience was of patients on dasatinib and how well it is tolerated? Is it likely all these symptoms are drug-related?
He is having a very good response to treatment, his most recent BCR/ABL was down to 0.383 down from 234.000 at diagnosis, but I do not think we should be reducing the dose of dasatinib at this stage which was his suggestion.

Any advice gratefully received.
Regards
Emma-Jane
Quick Reply

Reply to Emma-Jane McDonald

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
  • Jeff Lipton
  • Jeff Lipton's Avatar Topic Author
9 years 8 months ago #959 by Jeff Lipton
Replied by Jeff Lipton on topic CML and dasatinib
This is a hard question to answer. Generally dasatinib is well tolerated. In the first few weeks, some patients may have headaches or vague abdominal discomfort but this usually resolves. Long term, as is well known, you need to watch out for the pleural effusions or very very rarely the pulmonary arterial hypertension that has been associated with the use. Obviously no two patients are the same and there may be some issues that one patient may have that are not common. As you point out, you need to distinguish between a dasatinib side effect and something else. Rather than reduce the dose, I would be tempted to hold drug for a week or so and see if the symptoms improve. It should not take much longer than this to determine where you stand and then you can decide about rechallenging and whether at full dose or a slightly reduced dose initially, planning to increase the dose in the near future.
Despite how good TKI therapy, some patients just cannot cope with the diagnosis and thought of perhaps lifelong therapy. Given that in the case of both imatinib and dasatinib, there were GI side effects here, I would consider gastroscopy to rule out some upper GI pathology. Also keep in mind, not uncommonly, our patients are or get depressed and that may require intervention.
Quick Reply

Reply to Jeff Lipton

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
Moderators: Nicola, arlene